Melanoma Clinical Trials in Philadelphia

Showing 121-140 of 326 trials

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

NCT05498792

Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.

Locally Advanced or Metastatic Melanoma

Fox Chase Cancer Center12 participantsStarted Nov 2022

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530

The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).

Uveal MelanomaOcular MelanomaChoroidal Melanoma

Aura Biosciences22 participantsStarted Aug 2020

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +19 more locations

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Melanoma Trials in Other Cities

Dendritic Cell Vaccination in Patients With Advanced Melanoma

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Milademetan in Advanced/Metastatic Solid Tumors

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Other Conditions in Philadelphia